Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00093
|
|||||
| Drug Name |
Latanoprostene bunod
|
|||||
| Synonyms |
BOL-303259-X; BOL-303259-X1; NCX-116; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; PF-03187207; PF-3187207
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Renal cell carcinoma [ICD11: 2C90] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C27H41NO8
|
|||||
| Canonical SMILES |
C1C(C(C(C1O)CC=CCCCC(=O)OCCCCO[N+](=O)[O-])CCC(CCC2=CC=CC=C2)O)O
|
|||||
| InChI |
InChI=1S/C27H41NO8/c29-22(15-14-21-10-4-3-5-11-21)16-17-24-23(25(30)20-26(24)31)12-6-1-2-7-13-27(32)35-18-8-9-19-36-28(33)34/h1,3-6,10-11,22-26,29-31H,2,7-9,12-20H2/b6-1-/t22-,23+,24+,25-,26+/m0/s1
|
|||||
| InChIKey |
LOVMMUBRQUFEAH-UIEAZXIASA-N
|
|||||
| CAS Number |
CAS 860005-21-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 507.6 | Topological Polar Surface Area | 142 | ||
| Heavy Atom Count | 36 | Rotatable Bond Count | 18 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
4.4
|
|||||
| PubChem CID | ||||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OATP2B1 | Transporter Info | Organic anion transporting polypeptide 2B1 | Substrate | [2] | |
| References | ||||||
| 1 | Latanoprostene bunod was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci. 2010 May;51(5):2504-11. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.